New Velcade rival, looming Uloric patent loss will cost post-Shire Takeda growth: CEO FiercePharma
Takeda, in its first year counting the Shire business, has managed to turn up revenue growth. But the upcoming fiscal year could be a different story.
New Velcade rival, looming Uloric patent loss will cost post-Shire Takeda growth: CEO FiercePharma
Takeda, in its first year counting the Shire business, has managed to turn up revenue growth. But the upcoming fiscal year could be a different story.